Puma Biotech (PBYI) Reports In-Line Q2 EPS, Misses on Revenue; Offers FY24 Revenue Guidance

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $44.4 million versus the consensus estimate of $47.3 million.

GUIDANCE:

Puma Biotech sees FY2024 revenue of $183-190 million, versus the consensus of $217.6 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• MGE Energy VP of energy operations to retire at year-end
• Johnson Controls (JCI) 4K contracts of August 120 puts trade, share price down 4%